MAM
Aegis Media aims at widening profits in 2012
MUMBAI: Aegis Media expects to widen its profitability in India this year after breaking even in 2011 as it has set itself the target of doubling growth from each of its business verticals.
“We broke even in 2011. And we expect 2012 to be the first year when we will be significantly profitable,” says Aegis Media chairman (India) and CEO (South East Asia) Ashish Bhasin.
Aegis Media, part of Aegis Group, has four main businesses – media planning and buying; digital and search; Out-of-home and retail; and activation and creative.
“Our target for this year is that every business will have at least double the growth of their own category,” says Bhasin.
Aegis Media does not believe in a silo structure, the way many agencies are run. “We have a unique operating model in that sense. We give the clients all the benefits of specialisation without the hassles of silo-isation. And we are able to do it because we treat India as one country with one P&L (profit and loss).”
WPP, for instance, has its different agencies work independently and report to the parent company separately .
“We are media and agency agnostic. We can work with any agency. We are just media specific and we tell clients what combination of media is good for their product or brand,” Bhasin adds.
Aegis Media‘s aggressively intent got reflected late last year when it acquired a majority stake in Doosra Brand Communications to add creative capability to its India outfit.
So what will Doosra do for growth? “We are looking at quality rather than volume of work from there. We want them to have one or two marquee clients. Take few great companies and do path-breaking work for them, that‘s the direction we are looking at. We have also planned if at some later stage we can get into end-to-end film solution for clients,” says Bhasin.
What about Carat, Aegis Media‘s flagship brand, which was a loss-making outfit? “We had good clients in Carat but were not doing full justice to them. So for the last three years our focus has been to give them more attention and quality. So rather than going out for new businesses we wanted to service them well and get more businesses out of them. So for clients like Philips, of which we had only small part of their account, we now have 100 per cent of it,” says Bhasin.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
